{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T11:10:28Z","timestamp":1790075428712,"version":"4.0.1"},"reference-count":0,"publisher":"Bentham Science Publishers Ltd.","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CDT"],"published-print":{"date-parts":[[2026,9,18]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction:<\/jats:title>\n                    <jats:p>Peptic Ulcer Disease (PUD) remains a prevalent gastrointestinal condition\nprimarily caused by Helicobacter pylori infection and chronic NSAID use. Proton Pump Inhibitors\n(PPIs) are the mainstay therapy, promoting mucosal healing through profound gastric acid suppression.\nHowever, variable clinical outcomes are frequently observed, largely influenced by individual\ndifferences in PPI metabolism mediated by cytochrome P450 (CYP450) enzymes, especially\nCYP2C19 and CYP3A4.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>The review is a critical analysis of the evidence on PPI pharmacokinetics, pharmacogenomics,\nand drug-drug interactions based on a structured search of PubMed, Scopus, and\nWeb of Science, with predetermined inclusion and exclusion criteria to ensure equal consideration of\nstudies on the topic.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Genetic polymorphisms in CYP2C19 create distinct metabolizer phenotypes\u2014poor, intermediate,\nextensive, and ultrarapid\u2014that markedly influence PPI plasma levels, intragastric pH control,\nand ulcer healing rates. Poor metabolizers exhibit superior healing due to prolonged acid suppression,\nwhile ultrarapid metabolizers are prone to treatment failure. Rabeprazole and ilaprazole,\nshowing minimal CYP2C19 dependence, provide consistent efficacy across genotypes and reduced\ndrug interaction potential.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion:<\/jats:title>\n                    <jats:p>Pharmacogenomic variability in CYP2C19 significantly affects therapeutic response and\nadverse outcomes. Personalized therapy based on genotype can optimize PPI efficacy, minimize\ntoxicity, and reduce drug\u2013drug interactions, particularly with agents such as clopidogrel.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Incorporating CYP2C19 genotyping and pharmacogenomic data into clinical decisionmaking\nmay improve treatment individualization, although evidence remains heterogeneous and\ncontext-dependent.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2174\/0113894501451092260904093209","type":"journal-article","created":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T10:57:57Z","timestamp":1790074677000},"source":"Crossref","is-referenced-by-count":0,"title":["Cytochrome P450 Enzymes in the Metabolism of Proton Pump Inhibitors: Implications for the Treatment of Peptic Ulcers"],"prefix":"10.2174","volume":"27","author":[{"given":"Chetan Banbarilal","family":"Sharma","sequence":"first","affiliation":[{"name":"Department of Pharmacy, School of Medical and Allied Sciences, Galgotias University, Greater Noida, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2816-8273","authenticated-orcid":true,"given":"Shikha","family":"Yadav","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, School of Medical and Allied Sciences, Galgotias University, Greater Noida, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-6918-2789","authenticated-orcid":true,"given":"Shatrudhan","family":"Prajapati","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Lingaya\u2019s Vidyapeeth, Faridabad, Haryana,121002 India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","container-title":["Current Drug Targets"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0113894501451092260904093209","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/258513\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0113894501451092260904093209","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T10:58:01Z","timestamp":1790074681000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/258513\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,18]]},"references-count":0,"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0113894501451092260904093209","relation":{},"ISSN":["1389-4501"],"issn-type":[{"value":"1389-4501","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9,18]]}}}